Use of recombinant factor VIIa in symptomatic intracerebral hemorrhage following intravenous thrombolysis [PDF]
Clinics and Practice, 2015 Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial
Shadi Yaghi +4 more
doaj +2 more sources
Recombinant Factor VIIA. [PDF]
Med J Armed Forces India, 2009 Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of hemophilic patients with inhibitors and then used successfully for treating hemorrhages in patients with acquired hemophilia. In the last few years, along with the improvement in the knowledge of its mechanisms of action, rFVIIa has also been used with benefit as a “
Kinra P, Kumar H.
europepmc +4 more sources
Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients [PDF]
Korean Journal of Pediatrics, 2016 Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders.
Jeong A Park
doaj +2 more sources
Reduced thrombotic risk with recombinant factor VIIa in neonatal cardiac surgeryCentral MessagePerspective [PDF]
JTCVS OpenObjective: The study objective was to assess the effect of intraoperative recombinant factor VII administration on postoperative outcomes in neonates. Methods: Neonates were identified who underwent arterial switch operation, tetralogy of Fallot repair ...
Harrison Higgins, BS +6 more
doaj +2 more sources
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. [PDF]
Cochrane Database Syst Rev, 2015 In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'.
Matino D +4 more
europepmc +2 more sources
Recombinant factor VIIa: new insights into the mechanism of action through product innovation [PDF]
Research and Practice in Thrombosis and HaemostasisManagement of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa).
Miguel A. Escobar +9 more
doaj +2 more sources
The utility of recombinant factor VIIa as a last resort in trauma [PDF]
World Journal of Emergency Surgery, 2012 Introduction The use of recombinant factor VII (rFVIIa) as a last resort for the management of coagulopathy when there is severe metabolic acidosis during large bleedings in trauma might be deemed inappropriate.
Mamtani Rishi +5 more
doaj +2 more sources
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal. [PDF]
World J Emerg Surg, 2014 INTRODUCTION: Prothrombin complex concentrate (PCC) and recombinant Factor VIIa (rFVIIa) have been used for emergent reversal of warfarin anticoagulation. Few clinical studies have compared these agents in warfarin reversal. We compared warfarin reversal
Chapman SA +6 more
europepmc +2 more sources
Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope [PDF]
Archives of Medical Science, 2017 Xingshun Qi, Chun Ye, Xiaozhong Guo
doaj +2 more sources
Medication-Use Evaluation of Recombinant Human Factor VIIa [PDF]
Global Journal on Quality and Safety in Healthcare, 2020 Introduction: Medication-use evaluation (MUE) is a performance improvement method used to achieve optimal patient outcomes. The recombinant human factor VIIa (rFVIIa) (NovoSeven) is an expensive agent approved by the U.S.
Abrar Al-Subhi +2 more
doaj +1 more source